Category Archives: New York Stem Cells

New York, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Asia Pacific Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type, Applications, and Country" - https://www.reportlinker.com/p05974344/?utm_source=GNW High cost associated to the tissue engineering process is one of the major factors restraining the growth of the market.

Additionally, increasing financial contributions by government and private sector are likely to fuel the growth of the APAC tissue engineering market during the forecast period. Tissue engineering is a blend of material methods and cellular activities.This approach involves the use of physicochemical and biochemical attributes of humans to replace the biological tissues and strengthen them.

It is an innovative technology that works either separately or in conjunction with scaffolds, stem cells, regenerative medicine, and growth factors or negotiators. The process utilizes molecular and cellular processes in combination with the principles of material engineering to surgically repair and restore tissue. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period on the back of the increase in research activities, growing demand for organ transplants, rising number of initiatives by market players for expanding their presence in the region, and higher adoption of stem cell research in several APAC countries. China and India hold significant growth opportunities for players operating in the 3D bioprinting market, owing to the growing support from government bodies, increasing demand for cosmetic surgeries, and presence of less stringent regulations and data requirements than healthcare systems in developed countries. In July 2019, the Government of India collaborated with the US for the research and development of 3D bioprinting regenerative medicine.This collaboration involves the exchange of faculty members and students for the trade of scientific ideas/information and technologies, as well as the joint use of scientific infrastructure for research, especially in the field of 3D bioprinting.

The Government of South Korea announced plans to invest ~USD 37 million to boost the development of 3D bioprinting across the country. The country’s Ministry of Science announced plans to spend a considerable portion of its budget on a plethora of 3D bioprinting applications to strengthen its competitiveness and ability to meet demand. In APAC, due to an increasing number of COVID-19 infected patients, healthcare professionals and leading organizations are rechanneling the flow of healthcare resources from R&D to primary care, which is slowing down the process of innovation.Further, the COVID-19 pandemic is also hindering the conduct of clinical trials and drug development, and the operations of diagnostic industry in the region.

For instance, Stryker Corporation, a well-known player in the tissue engineering industry, has diverted operations to manufacture COVID-19 diagnostics and PPE kits.Moreover, according to a recent survey by Medscape in July 2020, substantial disruption has been witnessed in routine research activities that include tissue engineering and regenerative medicines as a result of the COVID-19 pandemic.

The rapid increase in the number of the infected patients in the India and China is likely to result in the slowdown of the market growth in the near future. In 2019, the biologically derived material segment accounted for the largest share of the APAC tissue engineering market.The growth of the market for this segment is attributed to the rising adoption of biomaterials due to their natural regenerative potential to restore tissue functioning and ability to facilitate the on demand release of chemokines with the procedure.

Further, the synthetic material segment is likely to register the highest CAGR in the market during the forecast period. A few of the significant secondary sources associated with the Asia Pacific tissue engineering market report are the World Health Organization (WHO), Government of India, Government of South Korea, and US Food and Drug Administration. Read the full report: https://www.reportlinker.com/p05974344/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More:
Asia Pacific Tissue Engineering Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Material Type, Applications, and Country -...

NBC News Shopping readers have a voracious appetite for learning about the many ways they can take care of their hair, whether with styling products, hot tools or otherwise. And since its National Hair Day, we rounded up 14 popular hair products, ranging from Gwenyth Paltrows favorite drugstore shampoo to a hair straightener favored by the stylist to Michelle Williams and Reese Witherspoon. We also include bestsellers from beauty retailers such as Sephora, Ulta and Dermstore, along with popular picks from department stores our readers frequently shop at, including, Macys and Nordstrom.

Dyson doesnt just specialize in vacuums and air purifiers (some of which ship within two days, if youre looking). One Shopping contributor previously called the Dyson SuperSonic Blow Dryer a light, compact and very sleek hair dryer that is designed for different hair textures. The futuristic-looking blow dryer comes with three magnetic attachments a smoothing nozzle, styling concentrator and diffuser that enables her to style and manage her curly 3B hair. The Dyson hair dryer has four heat settings, as well as three speed settings so you can customize your drying experience based on your hair needs.

In our guide to the best flat irons of 2020, celebrity hair stylists shared their all-time favorite hair straighteners they like to keep in their professional kits while helping Hollywood stars and musicians primp and prep for red carpet events. One expert-recommended product that Shopping readers gravitated toward was the ghd Classic Original IV Hair Straightener. "It's one of my favorites due to its semi-rounded edges, which increase the preservation of your hair's integrity and strength, so you don't accidentally repeat creases with frequent styling, which ultimately breaks your hair," said Kristen Shaw, hair stylist to Hilary Swank and Shailene Woodley.

Dealing with dry scalp can be a drag, which is why NBC News BETTER consulted Shari Hicks-Graham, MD, a dermatologist, on the best shampoos for dry scalp. Her number one recommendation was the LivSo Moisturizing Shampoo because its gentle, sulfate-free and contains xylitol to help fight yeast, while salicylic and glycolic acids, plus willow bark extract soothe your scalp. The LivSo Moisturizing Conditioner and LivSo Scalp Lotion happen to round out the top three most in-demand beauty products among NBC News Shopping readers.

Naturalistas can co-wash their hair with a hydrating hair product, such as Oribe Cleansing Creme for Moisture and Control, which was recommended by Vanessa Collington, a stylist at Mizu Hair Salon New York. [Oribes co-wash] cleans hair without stripping it of its natural oils, she told us in our guide to the best products for natural hair products. Its a heavier product for hair that is thicker and frizzy, so it also tames your curls. Orbies signature complex watermelon, lychee and edelweiss flower extracts protects the hair from oxidative stress and photoaging, according to the brand plus it smells delicious, too.

In our expert guide to coloring your hair at home, celebrity hair stylist and Garnier ambassador Nikki Lee recommended this affordable hair dye. Its made with a blend of hydrating oils avocado, shea, olive and fruit oil concentrate to help prevent your hair from drying out.

If your local barbershop isnt open, or they just dont feel comfortable leaving the crib, help them keep facial hair in check while at-home. Philips, which makes everything from an editor-approved electric toothbrush to ultrasound machines, created a trimmer with 19 attachments for both face and body via its Philips Norelco department.

This hot tool combines a blow dryer's power with the volume you typically achieve with a round brush at the hair salon. It uses a mix of nylon and tufted bristles to help detangle and smooth your strands while pumping up the volume. There are two speed and heat settings, too, along with a cooling option to help lock in your style. Revlons One-Step Hair Dryer and Volumizer Hot Air Brush is also an in-demand product for TODAY Show readers.

During Nordstroms Anniversary Beauty Sale, the Olaplex Hair Perfector No. 3 was one of the most popular beauty items among NBC News Shopping readers. While it isnt currently on sale, you can still snag the hair treatment from Nordstrom and other beauty retailers. The Hair Perfector is a weekly pH-balanced hair treatment that works on all hair textures from straight to kinky to help strengthen and protect your hair from damage.

Trade in your old curling iron with this 3-in-1 option from T3, a hot tool brand favored by celebrity hair stylists Kiki Heitkotter Michelle Williams and Reese Witherspoon are clients and Lauren Polko, who works with Priyanka Chopra and Adriana Lima. You can swap out your barrels, ranging from a 1-inch barrel for classic, defined curls; 1.25-inch barrel for a soft curl; and a 1.5-inch barrel for bombshell curls, like a Victoria's Secret model. If you prefer a curling wand instead of a curling iron, T3 also offers a set you can order instead.

Argan oil has a sweet, nutty aroma, as well as antioxidants and vitamins to help soften your hair. After you finish styling your hair with your hot tools, rub a small amount of this oil into the palm of your hands and run it through your hair to help keep frizz in check and leave behind a natural sheen and tropical scent. You can mix the oil into your deep conditioner for extra hydration, then put on a shower cap and use your standard blow dryer (or a hooded dryer if you have one) to help the ingredients penetrate your follicles.

This light-weight hair treatment conditions, hydrates and helps prep your hair for styling by offering heat protection. It was designed to be used as either a leave-in conditioner or you can wash the coconut oil-infused product out from your strands if you prefer. The L'Oral-owned brand also claimed this hair treatment helps control frizz, prevents static and reduces drying time.

Exfoliate your scalp with a gentle sugar crystal hair scrub to help remove product buildup and dandruff. The pH-balanced formula uses platinum fiber and pearl extract to impart a glass-like shine, while grape stem cells have antioxidants to revitalize your hair. Hyaluronic acid yes, the popular skin care ingredient is also found in this paraben- and sulfate-free, color-safe formula. Massage the scrub to damp hair, start at your scalp and work your way down to the end of your hair, then follow up with your shampoo and conditioner of choice.

In between wash days or after a workout, mist Living Proofs signature dry shampoo onto your oily scalp, to help soak up excess grease and help neutralize odor. You can also use this highly-rated dry shampoo, along with your curling iron or wand, to achieve beach waves at home, even if you dont live near the ocean. The cruelty-free formula is safe for both chemical- and color-treated hair since its free of sulfates.

Gwenyth Paltrow, actress and founder of Goop a lifestyle brand that sells a $75 candle that smells like her lady parts recently shared with Glamour that she uses this under $10 find, available on Walmart. Hydrate your hair with a caffeine-and-ginseng-infused conditioner, two ingredients the company says will help promote hair growth. Vitamin E will also help improve dullness and help prevent breakage.

Catch up on the latest from NBC News Shopping guides and recommendations and download the NBC News app for full coverage of the coronavirus outbreak

Nicole Saunders is the associate commerce editor at NBC News Shopping, covering wellness and lifestyle.

More:
Best hair products 2020: Shop hair dye, flat irons and more - NBC News

driven by high incidence of brain disorders and nerve injuries. The human nervous system comprises complex, delicate structures such as the spinal cord, the brain, and peripheral nerves, which are susceptible to different types of injuries.

New York, Sept. 29, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW Nerves constitute the most significant cable systems in the human body, performing the crucial job of carrying messages and information to brain and also to other parts of body. Whenever such critical nerves are injured, problems arise in muscles leading to sensation loss. Major types of nerve injuries include Neuropraxia, the physiologic blocking of nerve; Axonotmesis, the anatomic disruption of axon with slight disruption of connective tissue; and Neurotmesis, the anatomic disruption of connective tissue and nerve fibers.These injuries could result in trauma or more serious neurodegenerative diseases such as Parkinson`s disease, Alzheimer`s disease, multiple system atrophy, multiple sclerosis, and amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig`s disease).Alzheimer`s, Parkinson`s, Amyotrophic Lateral Sclerosis and multiple sclerosis are diseases that cause injury to the complex, delicate structures of the nervous system.Till date spinal cord injury and peripheral nerve damage are often permanent and incapacitating.

Innovative strategies are required for a shift in the paradigm and advanced treatment of these neurological injuries.But the question as to whether adult neurogenesis isrealstill remains unanswered with several contentious research studies still underway with no definitive answer to this century-long debate. Regrowth or repair of nervous tissues and cells involves generation of new neurons, glia, axons, myelin, or synapses.Gene Therapy is attracting immense research investments for its promise in promoting nerve regeneration and intraneural revascularization is being studied for its role in peripheral nerve regeneration.Newer studies are however dampening hopes by stating that adults produce no new cells in the hippocampus. Nevertheless, hopes of regeneration arecreating lucrative commercial opportunities as the pressure builds for newer and more effective treatment for neurological diseases.As the world awaits for a paradigm-shift in the treatment of neurological injury, neurostimulation and neuromodulation devices and biomaterials remains a massive multibilliondollar market worldwide. Neurostimulation and neuromodulation devices are currently available solutions to treat a variety of nerve injuries including peripheral nerve injuries. Neurostimulation and neuromodulation methods involve use of specially designed devices to transmit electrical impulses for controlling activity of the central nervous system and the brain.Internal neurostimulation and neuromodulation devices are growing in popularity for their significantly lower risk for post-surgical complications and shorter hospital stays. These include deep brain stimulation (DBS)for Parkinson`s, epilepsy and depression; spinal cord stimulation (SCS) for pain management and spasticity; gastric electrical stimulation (GES) for obesity and gastroparesis; vagus nerve stimulation (VNS) for depression and epilepsy; and sacral nerve stimulation (SNS) for constipation and urinary incontinence disorders.External neurostimulation devices, on the other hand, comprise transcutaneous vagus nerve stimulation (TVNS) for autism, depression, anxiety and age related disorders; transcutaneous electrical nerve stimulation (TENS)for chronic neuropathic pain and fibromyalgia disorders; transcranial magnetic stimulation (TMS)for depression and ADHD; and respiratory electrical stimulation (RES) for improving the respiratory function after spinal cord injury.

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE

II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW Nerve Repair and Regeneration Market Set for a Rapid Growth Neurostimulation and Neuromodulation Devices: Largest Product Segment Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

2. FOCUS ON SELECT PLAYERS Abbott Laboratories, Inc. (USA) AxoGen, Inc. (USA) Boston Scientific Corporation (USA) Integra LifeSciences Corporation (USA) LivaNova, PLC (UK) Medtronic plc (USA) NeuroPace, Inc. (USA) Nevro Corporation.(USA) Orthomed S.A.S. (France) Polyganics B.V. (The Netherlands) Stryker Corporation (U.S.) Synapse Biomedical Inc. (U.S.)

3. MARKET TRENDS & DRIVERS High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver Annual Incidence of Adult-Onset Neurologic Disorders in the US Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Global Alzheimers Prevalence by Age Group Diagnosed Prevalence Cases of Parkinson?s Disease Across Select Countries Classification of Nerve Injuries Recent Developments in Spinal Cord Injury Treatment Rising Geriatric Population and Subsequent Growth in Prevalence Of Neurological Disorders Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker Technological Advancements and Product Innovations - A Key Growth Driver Neurostimulation Allows Paralyzed People to Regain Leg Movement Neurostimulator to Treat Neurological Conditions Micro-Implantable Solution for Neurostimulation Parasym? Device for Neurostimulation Boston Scientific?s Spinal Cord Stimulation Improves Quality of Life Intellis? Platform Presents Smallest Implantable Neurostimulator Innovation in Deep Brain Stimulation for Parkinson?s Disease Innovations in Spinal Cord Stimulation for Pain Smart Neuromodulation: The Combination of AI and Neuromodulation Technologies New Dynamic Lead Interface Design for Neurostimulator Devices Wireless SCS Neuromodulation Therapy: An Alternative to Traditional SCS System Select Recent Approvals of Neuro-stimulation and Neuromodulation Devices Select Launches in Spinal Cord Stimulation (SCS) Market Select Launches in Deep Brain Stimulation (DBS) Market Select Neurostimulation Devices in Clinical Trials Select Neuromodulation Devices in Clinical Trials

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 2: World Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 3: World 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 5: World Historic Review for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 6: World 15-Year Perspective for Neurostimulation & Neuromodulation Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 8: World Historic Review for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 9: World 15-Year Perspective for Biomaterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 11: World Historic Review for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 12: World 15-Year Perspective for Neurostimulation & Neuromodulation Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 14: World Historic Review for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 15: World 15-Year Perspective for Neurorrhaphy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 17: World Historic Review for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 18: World 15-Year Perspective for Nerve Grafting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 20: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 21: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 23: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 24: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 26: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 27: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

GEOGRAPHIC MARKET ANALYSIS

UNITED STATES Table 28: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 29: USA Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 30: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 32: USA Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 33: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 35: USA Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 36: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 38: Canada Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 39: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 41: Canada Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 42: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 44: Canada Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 45: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

JAPAN Table 46: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 47: Japan Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 48: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 50: Japan Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 51: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 53: Japan Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 54: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CHINA Table 55: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 56: China Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 57: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 58: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 59: China Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 60: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 62: China Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 63: China 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

EUROPE Table 64: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2020 through 2027

Table 65: Europe Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 66: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 68: Europe Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 69: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 71: Europe Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 72: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 74: Europe Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 75: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

FRANCE Table 76: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 77: France Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 78: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 79: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 80: France Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 81: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 83: France Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 84: France 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

GERMANY Table 85: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 86: Germany Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Table 87: Germany 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Billion for the Years 2020 through 2027

Table 89: Germany Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Billion for Years 2012 through 2019

Here is the original post:
The global market for Nerve Repair and Regeneration is projected to reach US$12.7 billion by 2025 - Yahoo Finance

On Aug. 4, Hutchinson Regional Medical Center will open the Hutchinson Hematology and Oncology clinic. Dr. Sawsan Amireh will join the Hutch Regional team that day and see her first patients at her clinic which will be located in Suite 4 of Doctors Park at 2100 N. Waldron St., a building located to the southwest of the main hospital campus on the east side of Waldron Street.

Hematology and Oncology are two branches of medicine that continue to be a concern of members of our community and throughout the State of Kansas.

Oncology is the branch of medical science dealing with tumors, including the diagnosis and treatment of cancer. More than 1.8 million Americans, including 16,000 Kansans, are diagnosed with cancer each year. For more than 600,000 of our nations population each year, cancer is a terminal disease. The good news is that 17 million Americans are living out their lives as cancer survivors.

Cancer is best defined as the uncontrolled growth and spread of abnormal cells and the cause is often attributed to everything from heredity to an unhealthy lifestyle including tobacco use and excess weight. Treatments are medical, surgical, Chemotherapy and Radiation.

Hematology is the branch of medicine dealing with the cause, treatment and prevention of disease related to the blood. Specific issues dealt with include treatment of bleeding disorders, Lymphoma and Leukemia and blood transfusions, along with bone marrow and stem cell transplants.

Dr. Amireh, who has received training on the latest treatment protocols, arrives at Hutch Regional with impeccable credentials and is Board Certified in Internal Medicine. She received her doctorate degree in 2011 from the University of Jordan School of Medicine in Amman, Jordan. Since 2017, Dr. Amireh has participated in a Hematology and Oncology Fellowship and also served as chief fellow with the State University of New York Downstate Health Science Center in Brooklyn, New York. Also, Dr. Amireh served as Associate Chief Medical Resident and Internal Medical Resident at Saint Michaels Medical Center in New Jersey.

In 2010, Dr. Amireh completed special training at Vanderbilt University Medical Center in Nashville, Tennessee on Hepatology and Pediatric Endocrinology. She has won numerous awards and honors including the Clinical Documentation Excellence Award from St. Michaels Medical Center, the Academic Excellence Award from the University of Jordan School of Medicine, and the English Talented Writing Award from the University of Jordan.

Dr. Amireh is a member of the American Society of Clinical Oncology, American Society of Hematology, American College of Physicians, and the Jordan Medical Association.

Dr. Amireh said Oncology has entered a new era with the onset of COVID-19. "Cancer patients are now more vulnerable and will need to be more diligent to avoid infection which proves that life is more fragile than it once was," Dr. Amireh said. "I am looking forward to starting a hospital-based practice. We have a young family and southcentral Kansas is a good place to raise a two-year old. New York is too busy and not really family friendly."

"I want my practice to be inclusive and will welcome everyone who needs treatment and care," Dr. Amireh continued.

Appointments with Dr. Amireh will be accepted starting in Mid-July. Additional information including her clinics contact information will be published at that time.

With the opening of Hutchinson Hematology and Oncology, south central and western Kansas will have a new choice for quality cancer care. Dr. Amireh will provide a caring, personal approach to cancer care and her clinic will work in tandem with the Chalmers Cancer Center and the other Hutchinson Regional Healthcare System entities as well as other physician specialties in Hutchinson and surrounding communities to provide an integrated approach to care in Hutchinson.

Dr. Amireh will join her spouse, Dr. Mohammed "Mo" Al-Halawani at Hutch Regional. In July 2019, Dr. Al-Halawani joined Dr. Tariq Musa in opening Hutchinson Pulmonology Associates at Hutchinson Regional Medical Center. Dr. Al-Halawani and Dr. Musa hit the ground running and are serving patients in Hutchinson as well as an outreach clinic in McPherson, with plans to support pulmonary needs locally and in the surrounding areas.

We are excited that these high caliber healthcare professionals have chosen to move across America to provide their expertise to residents on the plains of Kansas.

Ken Johnson is the President and CEO of Hutchinson Regional Medical Center.

Originally posted here:
HRMC to open hematology and oncology clinic - The Ottawa Herald

NEW YORK, June 24, 2020 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing Natural Killer (NK) immunotherapies for cancer, today announces the appointment of Dr. Leila Alland and Ms. Jane Wasman to its Board of Directors, effective immediately.

Dr. Leila Alland brings extensive experience in oncology drug development to her role at Cytovia Therapeutics. Dr. Alland is currently Chief Medical Officer at PMV Pharma, a leader in the discovery and development of small molecule therapies targeting p53 mutations, which are prevalent in many cancers. Dr. Alland was previously Chief Medical Officer at Affimed, where she advanced the companys portfolio of clinical-stage immuno-oncology programs. During her career, she has held leadership positions at Tarveda Therapeutics, AstraZeneca, Bristol-Myers Squibb, Novartis and Schering-Plough, and has contributed to numerous successful oncology drug approvals over the course of her career, spanning both molecularly targeted and immuno-oncology therapeutic products. Dr. Alland is a member of the Scientific Advisory Council of Columbia University's Center for Radiological Research. Dr. Alland obtained her medical degree from New York University School of Medicine, completed her residency in pediatrics at The Childrens Hospital of Philadelphia and her fellowship in pediatric hematology/oncology at The New York Hospital and Memorial Sloan-Kettering Cancer Center, and was Assistant Professor of Pediatrics at Albert Einstein College of Medicine. I am very excited to be joining the Board of Directors at Cytovia Therapeutics, said Dr. Alland. Cytovias portfolio of immune therapeutics is steeped in the science of NK cells and the development of powerful new technologies that leverage the ability of NK cells to fight cancer. These novel technologies have the potential to go far beyond current drug development paradigms and make a real difference to individuals living with cancer.

Ms. Jane Wasman is a strategic leader with almost 25 years in the biopharma industry, with extensive U.S. and international experience. Ms. Wasman is Chair of the Board of Directors of Sellas Life Sciences, a board member at Rigel Pharmaceuticals, and serves on the board of NY BIO. Ms. Wasman is Founder and President of JWasman Advisors, (a consulting firm focused on strategic, operational and corporate governance matters for biopharma and life sciences organizations). She previously served as President, International, General Counsel and Chief, Strategic Development at Acorda Therapeutics, where she led long-range planning and development in addition to international expansion and in leadership positions including Vice President at Schering Plough. Ms. Wasman graduated magna cum laude from Princeton University, and earned her J.D. from Harvard Law School. I am thrilled to be able to joinCytovia's team who is implementing an agile partnership strategy and capital-efficient execution approach, said Ms. Wasman. I believe Cytovia Therapeutics is positioned to become a leading NK company with a differentiated product portfolio, leveraging two strong technologies - CAR NK and NK engager antibodies.

Dr. Daniel Teper, co-founder, Chairman and CEO of Cytovia Therapeutics, Inc stated:"We are delighted to welcome two exceptional industry leaders to our boardof directors. Cytovia Therapeutics is at a growth inflexion point where it can fully benefit from Dr. Alland's solid track record in oncology drug development and Ms. Wasman's expertise in corporate and financial transactions."

Media Snippets accompanying this announcement are available by clicking on the images or links below:

ABOUT CYTOVIA THERAPEUTICS, INCCytovia Therapeutics Inc is an emerging biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer and severe acute infectious diseases. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem and Macromoltek.

Learn more atwww.cytoviatx.com

Contact for media enquiries at Cytovia Therapeutics, IncSophie BadrVice President, Corporate AffairsSophie.badre@cytoviatx.com1(929) 317 1565

Here is the original post:
Cytovia Therapeutics, Inc Adds Two Industry Leaders to Its Board of Directors - GlobeNewswire

GAITHERSBURG, Md., June 03, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN) announced today that its strategic collaboration with the New York State Department of Health (DOH) to develop a state-of-the-art solution to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide is entering into its second year expansion phase. Having successfully achieved all of the milestones of the first year pilot phase for the development of an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance, OpGen will continue to work together with DOHs Wadsworth Center, participating healthcare systems, and collaborators such as Infectious Disease Connect, Inc. (IDC), which recently combined with ILM Health Solutions, to expand the reach of the platform, increase the volume of testing, and enhance data collection.

The DOH, OpGen, IDC and all stakeholders will continue to work collaboratively to demonstrate that a sustainable, flexible infectious diseases reporting, tracking and surveillance tool for antimicrobial resistance can be applied across New York State. The second-year expansion phase will build on the successes and experience of the first year pilot phase while focusing on accomplishing the goal of this visionary effort to improve patient outcomes and save healthcare dollars by integrating real-time epidemiologic surveillance with rapid delivery of antibiotic resistance results to care-givers via web-based and mobile platforms. OpGen is providing its Acuitas AMR Gene Panel for rapid detection of multidrug-resistant bacterial pathogens along with its Acuitas Lighthouse Software for high resolution pathogen tracking. The second year contract includes a quarterly retainer-based project fee as well as volume-dependent per test fees for a total contract value of up to $450,000 to OpGen.

We are excited and grateful that despite the continued threat of the COVID-19 pandemic which has hit New York State harder than any other place in the world, the Department of Health of New York State and the Wadsworth Center continue to work with us and have expanded their partnership for a second year, adding up to 3,500 AMR Gene Panel tests to be run, commented Oliver Schacht, CEO of OpGen. The quick spread of antimicrobial resistant superbugs across our healthcare systems is lurking below the current medical crisis. We anticipate that with our innovative diagnostic solutions we will be able to proactively identify such pathogens leading to early intervention and lifesaving treatment. A further project expansion of this nature may include the exploration of ways to achieve SARS-CoV-2 tracking.

Paul Edwards, Chief Strategy Officer at IDC commented, Our collaboration with OpGen allows us to not only identify bacteria and antimicrobial resistance down to the gene level but also to identify new or significant results versus phenotypic results alone. This molecular epidemiology capability in turn is critical in order to rapidly identify new clusters and outbreaks which otherwise would be missed and could potentially lead to outbreaks of hospital superbugs.

The precision medicine solutions provided by OpGen to accomplish the project goals are:

Wadsworth Center Director Dr. Jill Taylor said,"Under Governor Cuomo's leadership, New York State continues to lead the nation in addressing the threat of antimicrobial resistance. Working with our private-sector partners, the Wadsworth Center is able to further advance our mission to improve the public health of all New Yorkers.

About Antimicrobial-resistant InfectionsThe Centers for Disease Control and Prevention estimates that annually in the United States we face 2.8 million infections with 35,000 deaths and $49 billion in lost productivity all attributable to antibiotic resistant infections. Among the infectious diseases the parties are working to address are carbapenem-resistant Enterobacteriaceae (CRE) bacteria; they are untreatable and hard-to-treat infections on the rise among patients in medical facilities. CREs have become resistant to all or nearly all the antibiotics we have today. Almost half of hospital patients who get bloodstream infections from CRE bacteria die from the infection. The CDC has classified CREs as one of three urgent threats to the public health.

About Wadsworth Center LaboratoriesThe Wadsworth Center laboratories stand at the forefront of biomedical and environmental sciences and their interplay. The Center serves a vital role in the New York State Department of Healths efforts to protect and promote the health of New Yorks citizens. Building on more than a century of excellence as the states public health laboratory, the Center continues as a premier biomedical institute that merges clinical and environmental testing with fundamental, applied and translational research. Today, Wadsworth Center scientists use both classical and contemporary approaches to study environmental and biological questions related to human health and disease. They develop advanced methods to identify microbial or chemical threats; study drug resistance, emerging infections, and environmental exposures; manage the countrys most comprehensive diagnostic and environmental testing laboratory permit program; oversee extramural research programs on stem cells, breast cancer and spinal cord injury; and train the next generation of scientists through undergraduate, graduate, postdoctoral and visiting scientist programs.

About OpGen Inc.

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGens product portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.

For more information, please visit http://www.opgen.com.

Forward-Looking Statements

This press release includes statements regarding OpGens second year project phase with the New York State DOH. These statements and other statements regarding OpGens future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, our ability to successfully complete the second phase of the project with the New York State DOH, the rate of adoption of our products and services by hospitals and other healthcare providers, the realization of expected benefits of our business combination transaction with Curetis GmbH, the success of our commercialization efforts, the impact of COVID-19 on the Companys operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

OpGen:Oliver SchachtPresident and CEO[emailprotected]

OpGen Press Contact:Matthew BretziusFischTank PR[emailprotected]

OpGen Investor Contact:Joe GreenEdison Group[emailprotected]

Visit link:
OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections - GuruFocus.com

Global Stem Cells Cryopreservation Equipments Market

The Global Stem Cells Cryopreservation Equipments Market report consists of the latest discoveries and technological advancements recorded in the industry, along with an analysis of the factors and their effect on the markets future development. The report focuses on the current businesses and the present-day headways, and the future growth prospects for the Stem Cells Cryopreservation Equipments market.

This report covers the current COVID-19 effects on the economy. This outbreak has brought along drastic changes in world economic situations. The current scenario of the ever-evolving business sector and present and future appraisal of the effects are covered in the report as well.

The Global Stem Cells Cryopreservation Equipments market size will reach XX Million USD by 2027, from XX Million USD in 2019, at a CAGR of XX% during the forecast period.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/20434

The global Stem Cells Cryopreservation Equipments marketreport gives a 360 approach for a holistic understanding of the market scenario. It relies on authentically-sourced information and an industry-wide analysis to predict the future growth of the sector. The study gives a comprehensive assessment of the global Stem Cells Cryopreservation Equipments industry, along with market segmentation, product types, applications, and value chain.

The study also delivers accurate insights into the market in the forecast duration and other key facts and figures pertaining to the global Stem Cells Cryopreservation Equipments market.

Leading Stem Cells Cryopreservation Equipments manufacturers/companies operating at both regional and global levels:

Worthington IndustriesCharterCesca TherapeuticsShengjie Cryogenic EquipmentSichuan mountain verticalQingdao Beol

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research Objective:

Our panel of trade analysts has taken immense efforts in doing this group action in order to produce relevant and reliable primary & secondary data regarding the global Stem Cells Cryopreservation Equipments market. Also, the report delivers inputs from the trade consultants that will help the key players in saving their time from the internal analysis. Readers of this report are going to be profited with the inferences delivered in the report. The report gives an in-depth and extensive analysis of the Stem Cells Cryopreservation Equipments market.

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketexpertz.com/checkout-form/20434

Stem Cells Cryopreservation Equipments Market has maintained a steady growth rate in the past decade and is predicted to grow at a higher growth rate during the forecast period. The analysis offers an industry-wide evaluation of the market by looking at vital aspects like growth trends, drivers, constraints, opinions of industry experts, facts and figures, historical information, and statistically-backed and trade valid market information to predict the future market growth.

The Global Stem Cells Cryopreservation Equipments Market is segmented:

In market segmentation by types of Stem Cells Cryopreservation Equipments, the report covers-

Vapor phaseLiquid phase

In market segmentation by applications of the Stem Cells Cryopreservation Equipments, the report covers the following uses-

Other Stem Cells CryopreservationCord Blood Stem Cells Cryopreservation

This Stem Cells Cryopreservation Equipments report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Get Your Copy at Incredible [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/20434

Stem Cells Cryopreservation Equipments Market Regional Analysis:

Geographically, the Stem Cells Cryopreservation Equipments market is segmented across the following regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.

Key Coverage of Report:

Have a query? Ask our Expert @ https://www.marketexpertz.com/customization-form/20434

Key insights of the report:

Access the Entire Report with TOC, Tables and Figures, and details of Prominent [emailprotected] https://www.marketexpertz.com/industry-overview/stem-cells-cryopreservation-equipments-market

In conclusion, the Global Stem Cells Cryopreservation Equipments Market report provides a detailed study of the market by taking into account leading companies, present market status, and historical data to for accurate market estimations, which will serve as an industry-wide database for both the established players and the new entrants in the market.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

David is an Experience Business writer who regularly contribute to the blog, He specializes in manufacturing news

See the original post here:
Stem Cells Cryopreservation Equipments Market to Witness Sales Slump in 2020 Due to COVID-19| Long-term Outlook Remains Positive | Worthington...

A top New York University physician revealed plans to ensure that the four NYU hospitals in Manhattan, Long Island and Brooklyn will be better prepared and equipped to handle the potential recurrence of the coronavirus.

Dr. Fritz Francois, chief medical officer at NYU Langone Health, said hes planning on implementing the seven Ts to protect staff and patients: Tools, Testing, Teams, Triage, Treatments, Trials, and Throughput.

I cant emphasize enough how important it is for us to do research and publish what it is that we find, as opposed to just doing things anecdotally, he told Fox News.

Some experts have forecasted a potential second wave of coronavirus cases and deaths next fall that may be even more devastating than the current crisis.

In my mind, its inevitable that well have a return of the viruswhen it does, how we handle it will determine our fate, said Dr. Anthony Fauci, the director of the National Institute of Allergy and Infectious Diseases.

The second wave could be even more serious said Robert Redfield, M.D., director of the Centers for Disease Control and Prevention (CDC), according to Prevention.

Theres a possibility that the assault of the virus on our nation next winter will actually be more difficult than the one we just went through, he said.

Francois said that hes stocking up on tools such as personal protective equipment (PPE) as well as testing all incoming patients for COVID-19. NYU has developed precision teams to offer state-of-the-art care to patients, and upgrading triage teams by placing equipment outside hospital rooms to minimize the number of times staff needs to enter.

According to Fox News, NYU is conducting plasma and stem cells trials to determine the best treatment to fight the virus.

Throughput is in terms of how we do to ensure that patients can safely transition back home or to a rehab center when they beat the virus, Francois told Fox News.

2020 NewsmaxHealth. All rights reserved.

Read more:
Key Preparations for the Second Wave of Coronavirus - Newsmax

A newly-created mouse-human embryo contains up to 4% human cells the most human cells yet of any chimera, or an organism made of two different sets of DNA.

Surprisingly, those human cells could learn from the mouse cells and develop faster at the pace of a mouse embryo rather than a more slowly developing human embryo. That finding was "very serendipitous We did not really foresee that," said senior author Jian Feng, a professor in the department of physiology and biophysics at the State University of New York at Buffalo.

Successfully growing human cells in mouse embryos might one day help scientists understand the growth and aging process of our bodies and how diseases such as COVID-19 damage cells and could eventually even serve as a scaffold to grow organs for transplantation, Feng said.

Related: The 9 most interesting transplants

Feng and his team tackled a long-standing issue in creating such chimeras: that in order for human embryonic stem cells and mouse embryonic stem cells to chat and mingle, they needed to be in the same state of development. Embryonic stem cells are pluripotent, meaning they can develop into any type of cell in the body.

But "the human embryonic stem cell looks and behaves very differently from the mouse embryonic stem cell," so past attempts to get them to comingle have all failed, Feng told Live Science. At first, researchers thought the failures were due to some kind of species barrier; but after many years of study, they realized that it wasn't a species issue, but rather a maturity one.

The human stem cells were in a later stage of development called a "primed" state, which normally occurs only after the human embryo has already been implanted in the uterine wall. In contrast, the mouse stem cells were in a more "naive" state, which normally occurs when the mouse embryo is still floating around in the fallopian tubes. In the past, researchers weren't able to convert human cells back to this naive state, Feng said.

In their experiments, Feng and his team were inspired by a process called "embryonic diapause" that occurs in hundreds of mammals from bears to mice: When there's some sort of hardship such as a famine or shortage of water, some animals' embryos can remain in the naive state inside a mother's fallopian tubes for months and sometimes over a year for the environment to become more suitable, Feng said.

It's not clear what triggers the embryos to pause in this state, but a protein called mTOR seems to be a sensor that detects when conditions are bad, he said. Feng and his team figured out that they could target this protein inside human stem cells to make the cells think that they were experiencing famine, and needed to jump to a more naive state where they could conserve energy, Feng said.

The protein mTOR normally promotes the production of proteins and other molecules to support cell growth and proliferation, so by inhibiting it, Feng and his team "shocked" the human cells into changing their metabolism and gene expression. "So it behaves pretty much like the mouse cell," Feng said. What resulted was a naive set of human stem cells that could be cultured together with mouse stem cells and "intermingle very nicely," Feng said. The researchers then injected 10 to 12 of these naive human stem cells into mouse embryos.

In most of the mouse embryos, the naive human stem cells successfully developed into mature human cells in all three germ layers: the ectoderm, or the primary cell layers that develop when the embryo is growing and which later develop to form hair, nails, the epidermis and nerve tissue; the mesoderm, or the cells that make up the organs; and the endoderm, or the inner lining of organs. But no human cells spilled over into germline tissue, which develops into egg and sperm cells.

These germ layers then developed into more differentiated cells, and when the researchers stopped their experiment on the 17th day, 14 embryos were between 0.1% and 4% human (some had less human cells and some had more), with human cells found through the embryo, including in the liver, heart, retina and red blood cells.

Related: First pig-monkey chimeras were just created in China

But what was really "surprising" was the speed at which the human cells developed, Feng said. For example, the embryos were able to generate human red blood cells in 17 days, compared to the roughly 56 days red blood cells take to develop in a growing human embryo. Similarly, human eye cells don't develop until much later on in the embryo, whereas within 17 days, human eye cells including photo receptors formed in the chimera. Basically, the human cells "assumed the clock of the mouse embryo," Feng said. Previously, scientists thought this accelerated development was impossible because the tempo of human cell development was always thought to be "kind of immutable," he added.

This paper identifies a "novel way" of turning primed human pluripotent stem cells into a naive state, said Ronald Parchem, an assistant professor in the Stem Cells and Regenerative Medicine Center at Baylor College of Medicine in Texas, who was not a part of the study. But "the level of chimerism is low in this study," compared to another study that developed chimeras with up to 20% human cells per embryo, he said. That study, however, was published to the preprint database Biorxiv on May 24,and hasn't yet been peer-reviewed. "Together, these studies provide insight into capturing pluripotent states in vitro and highlight the barriers preventing successful cross-species chimerism," Parchem said. "Identifying ways to overcome these barriers has the potential to improve regenerative medicine."

These findings might "stimulate research" in the fundamental understanding of human development, especially how time is measured by biological systems, Feng said. Such chimeras could help scientists understand human diseases. For example, researchers might one day be able to regenerate human blood in a mouse model and study diseases such as malaria. Or if you can create human lung cells, or epithelial cells that line the respiratory tract, that mouse can become a "model system" for studying diseases like COVID-19, Feng said. In other words, mice with human cells can be infected with COVID-19 to understand how the virus attacks the body.

The most cited potential application of such chimeras is organ growth. But this likely won't happen in mice but much larger animals such as pigs, he said. Of course, these applications raise ethical issues, he added. One such ethical consideration is that chimeras blur the lines between species and that makes it difficult to determine the morality or the consciousness that those animals possess. For example, chimeras used in animal testing could be given too many human characteristics and have a similar moral status or consciousness to us, according to a previous Live Science report.

Feng said that much discussion needs to take place before such applications can be considered.

"This field requires much more exploration before this becomes a reality," said Carol Ware, the associate director at the University of Washington's Institute for Stem Cell and Regenerative Medicine, who was also not a part of the study. "A couple of the primary hurdles at this point are determining the host species for these human cells," and public acceptance in the work, she added.

"At this point, it would seem that the speed with which this clinical opportunity will become a reality will not be hindered by the ability to grow human organs," she added. "I would have liked to see," what happens when mTOR is taken away inside the lab dish and these naive human cells are allowed to advance again, particularly to see if some key cellular processes resume again, she added.

The findings were published in the journal Science Advances on May 13.

Originally published on Live Science.

See more here:
New human-mouse chimera is the most human yet - Livescience.com

Market Expertz has very recently published a report on the Stem Cell Banking market, which delves deeper into a bunch of insightful as well as comprehensive information about the Stem Cell Banking industrys ecosystem. The research report on the Stem Cell Banking market covers both qualitative as well as quantitative details that focus entirely on the various parameters such as Stem Cell Banking market risk factors, challenges, industrial developments, new opportunities available in the Stem Cell Banking report. These factors are the ones that determine the functioning and trends in the forecasted period for the market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

Avail your copy of the sample of the report on the global Stem Cell Banking [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/122606

With the growing number of new players entering the Stem Cell Banking market, expansion in businesses is also improving. Then Stem Cell Banking report focuses on boosting a series of parameters such as revenue shares, optimizing cost structure, offering better services, Stem Cell Banking market demand or supply chain, development policies, which mainly maps to streamline business processes during the projected timeline.

The fundamental drivers, as well as restraints, are identified by the recent trends and historical milestones gathered by the Stem Cell Banking market. It also demonstrates the brief evaluation of the investments, Stem Cell Banking production, innovative technologies, and growth rate of the specific businesses.

Leading Stem Cell Banking manufacturers/companies operating at both regional and global levels:

Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico).

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketexpertz.com/checkout-form/122606

The creative advancements are investigated widely to understand the probable impact on the growth of the global Stem Cell Banking market.

The Stem Cell Banking market has been segmented into key segments such as product types, end-users, leading regions, and noteworthy players. The readers can assess detailed and strategical information about each segment. The Stem Cell Banking market report also includes a blend of statistics about sales, consumption rate, volume, value, gross margin, and more.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Stem Cell Banking sector and can help companies in deciphering the optimum business move to reach their desired business goals.

product landscape:

Placental Stem Cells (PSCS), Adipose Tissue-Derived Stem Cells (ADSCS), Bone Marrow-Derived Stem Cells (BMSCS), Human Embryo-Derived Stem Cells , (HESCS), Dental Pulp-Derived Stem Cells (DPSCS)

Application landscape:

Sample Preservation and Storage, Sample Analysis, Sample Processing, Sample Collection and Transportation

End user landscape:

Personalized Banking Applications, Research, Clinical Application

The report includes accurately drawn facts and figures, along with graphical representations of vital market data. The research report sheds light on the emerging market segments and significant factors influencing the growth of the industry to help investors capitalize on the existing growth opportunities.

To get in-depth insights into the global Stem Cell Banking market, reach out to us @ https://www.marketexpertz.com/customization-form/122606

Thus, with the rising adoption of the Stem Cell Banking market in the international sector, the industry for the global Stem Cell Banking market is expected to represent a predicted outlook during the forecast phase from 2020-2027. Additionally, the report on the Stem Cell Banking market delivers a systematic representation of the growth opportunities, Stem Cell Banking market dynamics, and the existing trends are anticipated to shape the growth of the Stem Cell Banking market across the globe.

Geographically, this report studies the top producers and consumers in these key regions:

North America

Europe

China

Japan

Southeast Asia

India

A conscious effort is made by the subject matter experts to analyze how some business owners succeed in maintaining a competitive edge while the others fail to do so makes the research interesting. A quick review of the realistic competitors makes the overall study a lot more interesting. Opportunities that are helping product owners size up their business further add value to the overall study.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/122606

The Stem Cell Banking Market Research/Analysis Report addresses the following questions:

Read the full Research Report along with a table of contents, facts and figures, charts, graphs, etc. @ https://www.marketexpertz.com/industry-overview/2020-stem-cell-banking-global-market

To summarize, the global Stem Cell Banking market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

See the article here:
Impact of Covid-19 on Stem Cell Banking Market 2020: Remarking Enormous Growth with Recent Trends | Cord Blood Registry (CBR) Systems (US), Cordlife...